Chronic hepatitis C in Latinos: Natural history, treatment eligibility, acceptance, and outcomes

American Journal of Gastroenterology

Volumn 100, Issue 10, 2005, Pages 2186-2193

  Cheung, Ramsey C ^a,d   Currie, Sue ^b   Shen, Hui ^b   Ho, Samuel B ^c   Bini, Edmund J ^c   Anand, Bhupinderjit S ^c   Bräu, Norbert ^c   Wright, Teresa L ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c 154C ^*

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; REBETRON; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CAUCASIAN; CHRONIC HEPATITIS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ETHNOLOGY; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEEDLESTICK INJURY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRUS LOAD; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT ATTITUDE; PSYCHOLOGICAL ASPECT; VETERAN;

ADULT; ANTIVIRAL AGENTS; ELIGIBILITY DETERMINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPATITIS C, CHRONIC; HISPANIC AMERICANS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VETERANS;

EID: 27744536643     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.00240.x     Document Type: Article

References (23)

1. U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau, Available at : http://www.census.gov
2. Alter MJ Kruszon-Moran D Nainan O, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999 341 : 556 62.
3. Wiley TE Brown J Chan J. Hepatitis C infection in African Americans: Its natural history and histological progression. Am J Gastroenterol 2002 97 : 700 6.
4. Crosse K Umeadi OG Anania FA, et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2004 2 : 463 8.
5. Sterling RK Stravitz RT Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004 2 : 469 73.
6. Celona AF C Yu M Prakash M, et al. Hepatitis C in a Los Angeles public hepatitis clinic: Demographic and biochemical differences associated with race-ethnicity. Clin Gastroenterol Hepatol 2004 2 : 459 62.
7. Bonacini M Groshen MD Yu MC, et al. Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County. Am J Gastroenterol 2001 96 : 2438 41.
8. Reddy KR Hoofangle JH Tong MJ, et al. Racial differences in response to therapy with interferon in chronic hepatitis C. Hepatology 1999 30 : 787 93.
9. McHutchison JG Poynard T Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The international hepatitis intervention therapy group. Gastroenterology 2000 119 : 1317 23.
10. Muir AJ Bornstein JD Killenberg PG, et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004 350 : 2265 71.
11. Jeffers LJ Cassidy W Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004 39 : 1702 8.
12. Hepburn MJ Hepburn LM Cantu NS, et al. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004 117 : 163 8.
13. Cheung RC. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol 2000 95 : 740 7.
14. Briggs ME Baker C Hall R et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 2001 34 : 1200 5.
15. Roselle GA Danko LH Kralovic SM, et al. National Hepatitis C Surveillance Day in the Veterans Health Administration of the Department of Veterans Affairs. Mil Med 2002 167 : 756 9.
16. VA Centers of Excellence in Hepatitis C Research and Education. VA Treatment Recommendations for Patients with Chronic Hepatitis C: version 1.2. 1999.
17. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology 1997 26 : 2S 10.
18. Tedaldi EM Hullsiek KH Malvestutto CD, et al. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: The Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 2003 36 : 1313 7.
19. McHutchison JG Gordon SC Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1485 92.
20. Falck-Ytter Y Kale H Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002 136 : 288 92.
21. Muir AJ Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002 34 : 268 71.
22. Cawthorne CH Rudat KR Burton MS, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002 97 : 149 55.
23. Gaglio PJ Rodriguez-Torres M Herring R, et al. Racial differences in response rates to consensus interferon in HCV infected patients naïve to previous therapy. J Clin Gastroenterol 2004 38 : 599 604.